Despite current guidelines on asthma management, exacerbations of asthma are still prevalent, often requiring additional therapy such as inhaled and/or oral steroids, sometimes including hospital admission. This occurs particularly in patients with relatively severe disease during the fall season (1) . It is known that the presence of a common cold and allergen exposure are both associated with such exacerbations (2) (3) (4) . Epidemiologic evidence has shown that the combination of these two triggers is particularly harmful to patients with asthma (5) . However, there is lack of understanding regarding the pathogenic mechanisms involved.
Respiratory viruses are major triggers of asthma exacerbations (2) , in which rhinoviruses (RVs) appear to predominate (3, 6) . In epidemiologic studies, it has been shown that common colds are associated with an increase in asthma symptoms, vari-able airways obstruction, airway responsiveness, and features of lower airway inflammation (3, 6, 7) . Whereas experimental rhinovirus 16 (RV16) infections mimic these changes in patients with asthma (8) (9) (10) , the clinical responses to such experimental infections are relatively mild. It has been suggested that host factors such as atopy or airway hyperresponsiveness influence the host susceptibility to virus-induced changes (11) . Indeed, after upper respiratory tract infections, patients with asthma suffer from more frequent, severe, and longer lasting lower respiratory tract symptoms as compared with healthy subjects (12) . Hence, the asthmatic "airway milieu" may represent a favorable environment for viral infections, which might be associated with allergic airway inflammation.
The patient's natural exposure to environmental allergens can be mimicked using repeated low-dose allergen inhalations (13) . Such exposures have been shown to worsen most of the disease features in patients with pre-existing atopic asthma. This has been demonstrated with respect to increased airway hyperresponsiveness (4, 14, 15) as well as for an increase in eosinophilic inflammation (4, 15, 16) and Th2/Th1 cytokine balance (15) (16) (17) . It can be postulated that such inflammation could facilitate asthma exacerbations caused by subsequent respiratory virus infection.
The interaction between repeated low-dose allergen exposure and subsequent RV infection is not only plausible from an epidemiologic standpoint (1, 5) , but is also likely to occur at the cellular level within the airways. For instance, the presence of specific cytokines of ongoing allergic inflammation could lead to an increased expression of intercellular adhesion molecule-1, the receptor for the major group of RVs (18) , and increased susceptibility to subsequent RV infection (19) . Other possible mechanisms of interaction could be (1 ) switching of virus-specific CD8ϩ T cells from IFN-␥ to interleukin (IL)-5 production in the presence of IL-4 (20, 21); (2 ) worsening of an asthma exacerbation by combined eosinophilic and neutrophilic inflammation (9, (22) (23) (24) , possibly because of the degranulation of eosinophils by neutrophil proteases (25) ; and/or (3 ) eosinophils participating in an RV-induced immune response through antigen presentation and T-cell activation (26) .
Therefore, in this study, we postulated that repeated lowdose allergen exposure preceding experimental RV16 infection increases the severity of an RV-induced asthma exacerbation and thus leads to a flare-up of symptoms, medication use, variability of airways obstruction, airway hyperresponsiveness, and airway inflammation. To that end, we exposed patients with mild to moderate atopic asthma to low doses of house dust mite allergen for 2 weeks, RV16 infection, or the combination of the two.
METHODS
The extended version of the methods is available in the online supplement. Thirty-six steroid-naive atopic patients with mild to moderate asthma participated (Table 1 ) (see Table E1 in the online supplement for details of the patients' characteristics). The Medical Ethics Committee of the Leiden University Medical Center approved the study, and the subjects gave written informed consent before entering. The study had a placebo-controlled, double-blind, parallel, three-armed design ( Figure 1 ). The thirty-six patients were randomly assigned to either low-dose allergen exposure with placebo infection (allergen ϩ placebo; n ϭ 12), placebo exposure with RV16 infection (placebo ϩ RV16; n ϭ 12), or low-dose allergen exposure with subsequent RV16 infection (allergen ϩ RV16; n ϭ 12). Screening high-dose allergen challenges were performed according to a standardized protocol (27, 28) , with purified aqueous allergen extract of Dermatophagoides pteronyssinus (SQ 503; ALK Abelló , Nieuwegein, the Netherlands). Subjects had a documented early and late response. The noncumulative dose of allergen causing a fall in FEV 1 of 5% from postdiluent baseline during this allergen challenge was selected as the low dose to be used for repeated allergen exposure. The patients inhaled this daily on working days as a single dose for 2 consecutive weeks ( Figure 1 ). Spirometry was done before and 10, 20, and 30 minutes after inhalation on each occasion (16) .
RV16 inoculation was done by nasal administration of a total dose of 0.4-8.6 ϫ 10 4 50% tissue culture infective dose (TCID 50 ) diluted in 3 ml of Hanks' balanced salt solution to each subject according to a previously described procedure (8, 29) . Confirmation of RV16 infection was established by a fourfold or greater increase in virus-specific neutralizing antibody titer in serum and/or by recovery of the virus from the nasal lavages (8, 29) . FEV 1 , provocative concentration of histamine causing 20% fall in FEV 1 (PC 20 FEV 1 ) to histamine (27) , exhaled nitric oxide (NO) measurements (30), sputum inductions, and nasal lavages were performed according to the study schedule represented in Figure 1 . Asthma symptom scores, cold scores, salbutamol usage, and PEF measurements were recorded three times daily in diary cards during the 7 weeks of the study (16, 22, 31, 32) .
Sputum was induced and processed according a protocol that has been validated in our laboratory (16, 33) . In the sputum supernatant, concentrations of eosinophil cationic protein and levels of neutrophil elastase and IL-8 were determined by enzyme immunoassay (16, 22, (33) (34) (35) .
Nasal lavages were obtained using a modified "nasal pool device" (9, 22) . The lavages recovered from the first (Hanks' balanced salt solution) and second nostril (phosphate-buffered saline) were used for confirmation of RV16 infection and to determine the cell numbers and mediator level, respectively. Levels of IL-8 were determined by ELISA.
For sample size estimation and statistical power, see the online supplement. The cold score was analyzed using the Mann-Whitney U test to test between-group differences (SPSS 10.0; SPSS Inc., Chicago, IL). The longitudinal data were analyzed using a random-effects model to explore allergen-induced, RV16-induced, and allergen ϩ RV16-induced changes in asthma symptoms, ␤ 2 -agonist usage, PEF values, FEV 1 , (log-transformed) PC 20 FEV 1 , exhaled NO, and sputum and nasal lavage data (36) . The STATA 6.0 xtreg procedure (StataCorp, College Station, TX) was used to fit the applied random-effects model. A p value of 0.05 or less was considered statistically significant.
RESULTS
In the majority of patients (21 out of 24) who were inoculated with RV16, RV infection was confirmed, whereas in three (patients 6, 13, and 20), it was not. Patients 28 and 29 in the allergen group had an intercurrent spontaneous "common cold" with RV. Two patients dropped out of the study because of an asthma exacerbation. Patient 24 had a spontaneous exacerbation during the beginning of the study, during the placebo-allergen period. Patient 3 developed an RV-induced exacerbation on the 2nd day of RV16 inoculation (Day 16), after 2 weeks of allergen exposure. The sums of the cold scores and asthma scores that day were 42 and 30, respectively. PEF decreased to 28% of personal best. The patient was withdrawn from the study and admitted to our hospital for 1 night. The patient was treated with oxygen, inhaled ipratropium/salbutamol, and prednisone orally and recovered quickly during the night and following days. The results from these seven patients were excluded from the analysis (see Table E1 for details). There were no differences in baseline values for any of the measurements between the groups (p Ͼ 0.06).
The acute response to a low dose of allergen exposure as assessed by the mean maximal fall in FEV 1 Ϯ SD within 30 min after low-dose allergen exposure was 5.97 Ϯ 1.68% in the combined allergen ϩ placebo and allergen ϩ RV16 groups as compared with 1.40 Ϯ 0.63% in the placebo ϩ RV16 group (p Ͻ 0.001).
Between-intervention differences with corresponding 95% confidence intervals are outlined in Table 2 . There were significant changes during the 2 weeks of low-dose allergen exposure in most of the parameters as compared with placebo inhalations (discussed later here). However, the differences between the interventions were not maintained beyond the 2 weeks of allergen exposure for any of the parameters.
Asthma Symptom Score, Cold Score, PEF Measurements, and ␤ 2 -Agonist Usage
During allergen exposure, the asthma symptom score (p ϭ 0.001), lowest morning/highest PEF (p ϭ 0.009), and ␤ 2 -agonist usage (p Ͻ 0.001) changed significantly ( Figure 2 ). RV16 infection either after allergen exposure or not after allergen exposure did not result in a significant further change of these parameters. After RV16 infection, the cold score increased significantly in both the allergen ϩ RV16 group (median cold score, 7.5; range, 0-14, p ϭ 0.048) and the placebo ϩ RV16 group (cold score, 5.0; range, 3-14, p ϭ 0.006) as compared with the allergen ϩ placebo group (cold score, 2.0; range, 0-5). There were no significant differences in cold score between the allergen ϩ RV16 group and the placebo ϩ RV16 group (Figure 3) .
FEV 1 and Airway Hyperresponsiveness
Allergen exposure resulted in a significant decrease in FEV 1 (p Ͻ 0.001) and PC 20 FEV 1 (p Ͻ 0.001) (Figures 4 and 5 ). RV16 infection also led to a drop in FEV 1 (p ϭ 0.02) but did not result in a significant decrease in PC 20 FEV 1 (p ϭ 0.2). Successive allergen exposure and RV16 infection showed a borderline significant increase in FEV 1 (p ϭ 0.052) and no additive changes in PC 20 FEV 1 (p ϭ 0.3).
Exhaled NO
Exhaled NO increased during allergen exposure (p Ͻ 0.001), whereas it did not change significantly after RV16 infection (p ϭ 0.8). Successive allergen exposure and RV16 infection did not change exhaled NO significantly (p ϭ 0.9) as compared with allergen alone (Figure 6 ).
Sputum Eosinophils, Neutrophils, Eosinophil Cationic Protein, Neutrophil Elastase, and IL-8
Repeated allergen exposure resulted in a significant increase in sputum eosinophils (p Ͻ 0.001), whereas RV16 infection significantly increased sputum neutrophils (p ϭ 0.01) (Figure 7) . Moreover, RV16 infection also resulted in an increase in sputum eosinophil cationic protein, which was on the border of significance (p ϭ 0.054) and significant increases in sputum neutrophil elastase (p ϭ 0.04) and IL-8 (p ϭ 0.04). RV16 infection after allergen exposure did not result in an additive effect in any of the parameters.
Nasal Lavage Eosinophils, Neutrophils, and IL-8
The percentage of nasal neutrophils (p ϭ 0.005), as well as nasal IL-8 (p ϭ 0.04), increased during RV16 infection, which was accompanied by a drop in the percentage of nasal eosinophils (p ϭ 0.003). There were no significant additive changes in the allergen ϩ RV16 group.
DISCUSSION
In this study, we found that "priming" the airways with repeated low-dose allergen exposure does not result in an aggravated response with regard to airways obstruction and airway inflammation after RV infection in patients with mild asthma. When given alone, allergen exposure and RV16 infection each resulted in a significant decrease in FEV 1 . Interestingly, PC 20 , exhaled NO, and the percentage of sputum eosinophils changed during allergen exposure, whereas sputum neutrophils, neutrophil elastase, and IL-8, and nasal neutrophils and IL-8 increased after RV16 infection. Hence, repeated low-dose allergen exposure and RV16 infection induce distinct inflammatory profiles within the airways in patients with asthma. However, we did not observe any interaction between these two environmental triggers. This indicates that preceding allergen exposure, in the used study design, is not a major determinant of the severity of RV-induced asthma exacerbations in patients with mild asthma. This is the first study in which the effects of repeated lowdose allergen exposure on the response to a subsequent RV infection in patients with asthma have been investigated. First, our findings during low-dose allergen exposure alone is in line with those of previous studies showing worsening of airway hyperresponsiveness (4, 14, 15) , increased exhaled NO (16) , and an increased eosinophilic inflammation (4, 15, 16) . They also confirm inflammatory changes seen in sputum and nasal lavage after RV infection (9, 22) . However, whereas there is good evidence of the reverse interaction, namely of RV infection on subsequent Using the Mann-Whitney U test, the cold score increased significantly after RV16 infection, in both the allergen ϩ RV16 group (p ϭ 0.048), as well as in the placebo ϩ RV16 group (p ϭ 0.006) as compared with the allergen ϩ placebo group (depicted by an asterisk). There were no significant differences in scores between the allergen ϩ RV16 group and the placebo ϩ RV16 group.
allergen-induced airways obstruction and inflammation (37, 38), we found no evidence that allergen exposure worsens subsequent RV-induced responses. Noticeably, our data are not suggestive of any protective effects of preceding allergen challenge on cold symptoms or nasal inflammation, as reported by Avila and colleagues (39) . Therefore, it seems as if the epidemiologic evidence of allergen-virus interactions during asthma exacerbations (5) cannot simply be explained by allergen-induced "priming" of the responses to RV infection by the lower airways.
The lack of interaction between repeated low-dose allergen exposure and subsequent RV16 infection could theoretically be due to method choices. Our design was mainly driven by safety considerations. We selected steroid-naive patients to avoid any confounding effect of antiinflammatory therapy. In addition, the low-dose allergen exposure was meant to be a mild inducer of inflammation, which by itself would not lead to an exacerbation of the disease (16) . Nevertheless, this study and our previous one (16) have shown that this model results in definite physiologic and inflammatory changes. However, it cannot be excluded that there could be an interaction between the two interventions using a higher dose of allergen. It also cannot be excluded that the timing of subsequent RV infection may not have been optimal, as there was a 3-day interval between measuring the effects of repeated low-dose allergen and the RV16 inoculation. This may not effectively mimic the real-life situation and could be a possible reason for a lack of interaction between the two interventions. We used an RV16 inoculum that was known to be safe and for that very reason may exhibit limited virulence in vivo when compared with natural occurring common colds (8-10). Although we could not confirm RV-induced worsening of airway hyperresponsiveness (9), we did observe increases in cold scores next to an increase in neutrophil counts in sputum and nasal lavages. Finally, we cannot exclude that our failure to detect interaction between allergen exposure and RV16 infection was due to lack of statistical power. The absence of worsening in hyperresponsiveness after RV alone, in this and other studies (40) , could be suggestive of this. However, it appeared that each of the triggers by themselves induced adequate (but distinct) inflammatory profiles within the airways, as required for potential interaction.
How can these results be explained? When developing our hypothesis, we postulated that ongoing allergic inflammation would facilitate or augment virus-induced proinflammatory responses in the airways. There are multiple potential pathways for this, which we did not specifically explore in this study. First, allergen-induced IL-4 release could impair viral clearance by a switch in CD8ϩ T-cell cytokine profile (IFN-␥ to IL-5) (21) and/or a reduction in cytotoxic activity (20, 41) . Although exhaled NO may reflect allergic inflammation in asthmatic airways (42) , allergen-induced impaired synthesis of protective nitric oxide might disturb defensive response against viral infection (43) . Second, allergen-induced cytokines increase the expression of the major RV receptor intercellular adhesion molecule-1 (18) . Third, combined eosinophilic and neutrophilic airway inflammation may enhance eosinophilic degranulation through neutrophil protease activity (25) . In this proof of concept study, we have not attempted to investigate these putative mechanisms specifically because this would have required invasive measurements, such as bronchial biopsies. Apparently, none of these mechanisms are leading to manifest interaction with regard to the clinical and physiologic responses in patients with mild asthma. However, it cannot be excluded that these interactive pathways might have been balanced by potential protective mechanisms between allergens and virus infections, such as expression of antiinflammatory mediators (e.g., IFN-␥ and IL-10), local production of NO, or antiviral effects of eosinophil products (39, 44) .
Nevertheless, clinical and epidemiologic data (5, 24) favor additive or synergistic responses to allergens and virus infections in asthma. It can be envisaged that such an interaction during asthma exacerbations can also be dependent on specific host characteristics or more severe degrees of the disease. First, patients with asthma who are susceptible for RV-induced asthma exacerbations could have relatively high IgE levels. Duff and colleagues (45) have shown that high IgE levels together with RV infections are synergistic risk factors for wheezing with colds. Furthermore, very recent data indicate that high levels of total serum IgE are also predictive of lower respiratory tract symptoms after experimental rhinovirus infection in patients with asthma (46) . Second, host factors such as an altered balance between proinflammatory IL-1␤ and antiinflammatory IL-1ra could also influence virus-induced inflammation and symptoms (47) (48) (49) . Finally, diminished antiviral activity could also occur in patients with a decreased production of IFN-␥ (50). Therefore, phenotypic characteristics need to be investigated in the future search for the determinants of severe asthma exacerbations. Obviously, there are ethical restraints to the induction of exacerbations by using experimental infections in patients with more severe asthma so that most of the information should be derived from observational studies. Eventually, this may characterize the patients who are particularly vulnerable to RV infections and may allow the development of novel strategies to prevent/ treat exacerbations in asthma. 
